


PHENTERMINE HYDROCHLORIDE - phentermine hydrochloride tablet
Dispensing Solutions, Inc.

PHENTERMINE
HYDROCHLORIDE
TABLETS USP, 37.5 mg CIV

Rx only

DESCRIPTION

Phentermine hydrochloride USP has the chemical name of α, α -Dimethylphenethylamine hydrochloride. The structural formula is as follows:



$C_{10}H_{15}N \cdot HCl$

M.W. 185.7

Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.

Phentermine hydrochloride, an anorectic agent for oral administration, is available as a tablet containing 37.5 mg of phentermine hydrochloride (equivalent to 30 mg of phentermine base).

Phentermine hydrochloride tablets contain the inactive ingredients: crospovidone, dibasic calcium phosphate dihydrate, magnesium stearate, povidone, propylene glycol, FD&C Blue #1 Aluminum Lake, shellac glaze, and titanium dioxide.

CLINICAL PHARMACOLOGY

Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example.

Adult obese subjects instructed in dietary management and treated with "anorectic" drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.

The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss

appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator; the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks' duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

INDICATIONS AND USAGE

Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m², or ≥ 27 kg/m² in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia).

Below is a chart of Body Mass Index (BMI) based on various heights and weights.

BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds $\div 2.2$ = kg; inches $\times 0.0254$ = meters.

BODY MASS INDEX (BMI), kg/m²

Weight (pounds)	Height (feet, inches)					
	5'0"	5'3"	5'6"	5'9"	6'0"	6'3"
140	27	25	23	21	19	18
150	29	27	24	22	20	19
160	31	28	26	24	22	20
170	33	30	28	25	23	21
180	35	32	29	27	25	23
190	37	34	31	28	26	24
200	39	36	32	30	27	25
210	41	37	34	31	29	26
220	43	39	36	33	30	28
230	45	41	37	34	31	29
240	47	43	39	36	33	30
250	49	44	40	37	34	31

The limited usefulness of agents of this class (see **CLINICAL PHARMACOLOGY**) should be measured against possible risk factors inherent in their use such as those described below.

CONTRAINDICATIONS

Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.

Agitated states.

Patients with a history of drug abuse.

During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).

WARNINGS

Phentermine hydrochloride tablets are indicated only as short-term monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss, including selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of these drug products for weight loss is not recommended.

Primary Pulmonary Hypertension (PPH) – a rare frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms include: angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema.

Valvular Heart Disease: Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.

Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.

Phentermine hydrochloride may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

Usage with Alcohol: Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.

PRECAUTIONS

General

Caution is to be exercised in prescribing phentermine hydrochloride for patients with even mild hypertension.

Insulin requirements in diabetes mellitus may be altered in association with the use of phentermine hydrochloride and the concomitant dietary regimen.

Phentermine hydrochloride may decrease the hypotensive effect of guanethidine.

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies have not been performed with phentermine hydrochloride to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.

Pregnancy – Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with phentermine hydrochloride. It is also not known whether phentermine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Phentermine hydrochloride should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Cardiovascular: Primary pulmonary hypertension and/or regurgitant cardiac valvular disease (see **WARNINGS**), palpitation, tachycardia, elevation of blood pressure.

Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache; rarely psychotic episodes at recommended doses.

Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

Allergic: Urticaria.

Endocrine: Impotence, changes in libido.

DRUG ABUSE AND DEPENDENCE: Phentermine hydrochloride is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phentermine hydrochloride should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.

OVERDOSAGE

Manifestations of acute overdosage with phentermine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.

Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine[®], CIBA) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage.

DOSAGE AND ADMINISTRATION

Exogenous Obesity: Dosage should be individualized to obtain an adequate response with the lowest effective dose.

The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1 – 2 hours after breakfast. The dosage may be adjusted to the patient's need. For some patients 1/2 tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give 1/2 tablet (18.75 mg) two times a day. Late evening medication should be avoided because of the possibility of resulting insomnia. Phentermine is not recommended for use in patients sixteen (16) years of age and under.

HOW SUPPLIED

Phentermine hydrochloride tablets USP 37.5 mg (equivalent to 30 mg phentermine base) are white with blue specks, oval shaped, scored on one side and debossed MP 273 on the other side.

Bottles of 30	NDC 53489-406-07
Bottles of 60	NDC 53489-406-06
Bottles of 100	NDC 53489-406-01
Bottles of 250	NDC 53489-406-03
Bottles of 500	NDC 53489-406-05
Bottles of 1000	NDC 53489-406-10

Store at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature]

DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.

Manufactured by:
MUTUAL PHARMACEUTICAL CO., INC.
Philadelphia, PA 19124 USA

Rev 01, February 2009


PRINCIPAL DISPLAY PANEL


BULK SOURCE DATA
MFR: MUTUAL PHARMACEUTICAL CO., INC.
PHILADELPHIA, PA 19124

PRODUCT ID:
WHITE / BLUE SPECKS OVAL
SCORED TABLET DEBOSSSED
MP 273

BULK SOURCE NDC: 53489-0406-10
MFR. LOT: [REDACTED]
PEDIGREE #: [REDACTED]

DISPENSE IN THIS
TIGHT/LIGHT RESISTANT CONTAINER





PHENTERMINE HCl 37.5 mg
[REDACTED] TABLETS
NDC 66336-0344-[REDACTED]
PRODUCT # 706-[REDACTED]

EACH TABLET CONTAINS:
PHENTERMINE HYDROCHLORIDE USP 37.5 mg
(EQUIVALENT TO 30 mg OF PHENTERMINE BASE)
WARNING: MAY BE HABIT FORMING.

LOT# [REDACTED] EXP: [REDACTED] Rx # [REDACTED]
RX ONLY


CAUTION: FEDERAL LAW PROHIBITS THE TRANSFER OF THIS DRUG TO
ANY PERSON OTHER THAN THE PATIENT FOR WHOM IT WAS PRESCRIBED.

**WARNING: KEEP OUT OF
CHILDREN'S REACH
STORE AT 68° - 77° F. SEE USP.**

706- [REDACTED] NDC 66336-0344- [REDACTED]
PHENTERMINE HCl 37.5 mg
C-4 TABLETS
LOT # [REDACTED] EXP: [REDACTED]
MN 53489-0406-10 RX# [REDACTED]

706- [REDACTED] NDC 66336-0344- [REDACTED]
PHENTERMINE HCl 37.5 mg
C-4 TABLETS
LOT # [REDACTED] EXP: [REDACTED]
MN 53489-0406-10 RX# [REDACTED]

706- [REDACTED] NDC 66336-0344- [REDACTED]
PHENTERMINE HCl 37.5 mg
C-4 TABLETS
LOT # [REDACTED] EXP: [REDACTED]
MN 53489-0406-10 RX# [REDACTED]



Packaged Exclusively By:
DISPENSING SOLUTIONS^{INC}
Santa Ana, CA 92704

NDC 66336-0344-XX

NDC 66336-0344-07
NDC 66336-0344-14
NDC 66336-0344-15
NDC 66336-0344-28
NDC 66336-0344-30
NDC 66336-0344-45
NDC 66336-0344-56
NDC 66336-0344-60
NDC 66336-0344-84

**PHENTERMINE
HYDROCHLORIDE
TABLETS USP**

37.5 mg

Rx only

Phentermine Hydrochloride				
phentermine hydrochloride tablet				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:66336-344(NDC:53489-406)	
Route of Administration	ORAL	DEA Schedule	CIV	
Active Ingredient/Active Moiety				
Ingredient Name			Basis of Strength	Strength
Phentermine Hydrochloride (UNII: 0K2I505OTV) (Phentermine - UNII:C045TQL4WP)			Phentermine Hydrochloride	37.5 mg
Inactive Ingredients				
Ingredient Name			Strength	
povidone (UNII: FZ989GH94E)				
Product Characteristics				
Color	white (with blue specks)		Score	no score
Shape	OVAL (Scored on one side)		Size	13mm
Flavor			Imprint Code	MP;273
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:66336-344-07	7 in 1 BOTTLE		
2	NDC:66336-344-14	14 in 1 BOTTLE		
3	NDC:66336-344-15	15 in 1 BOTTLE		
4	NDC:66336-344-28	28 in 1 BOTTLE		

5	NDC:66336-344-30	30 in 1 BOTTLE		
6	NDC:66336-344-45	45 in 1 BOTTLE		
7	NDC:66336-344-56	56 in 1 BOTTLE		
8	NDC:66336-344-60	60 in 1 BOTTLE		
9	NDC:66336-344-84	84 in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040527	10/23/2003	

Labeler - Dispensing Solutions, Inc. (066070785)

Registrant - PSS World Medical, Inc. (101822682)

Establishment

Name	Address	ID/FEI	Business Operations
Dispensing Solutions, Inc.		066070785	relabel, repack

Revised: 2/2012

Dispensing Solutions, Inc.